Dr. Iams on Small Cell Lung Cancer Subtyping in Clinical Practice
Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.
Dr. Iams on the Evaluation of Sotorasib in KRAS G12C–Mutant Solid Tumors
Wade T. Iams, MD, discusses the evaluation of sotorasib in KRAS G12C–mutant solid tumors, including non–small cell lung cancer.
Dr. Iams on Establishing the Clinical Utility of ctDNA Testing in Lung Cancer
Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.
Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer
Wade T. Iams, MD, discusses the emergence of TKIs and antibody-drug conjugates in HER2-mutant lung cancer.
Neoadjuvant Immunotherapy May Change Standard of Care in Early-Stage NSCLC
Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512